HR 4981 Re-checks Congress.gov for new actions and updates the bill's status, and fills in any sponsors, committees, or related bills that are missing. It does not re-pull sponsors/cosponsors/committees/related — those rarely change — and it skips all work if nothing has changed upstream, so it's cheap to click.
To provide for the issuance of a Lyme Disease Research Semipostal Stamp.
Summary
This bill directs the United States Postal Service to issue a special Lyme Disease Research Semipostal Stamp. All proceeds from the sale of the stamp beyond the standard postage rate would be transferred to the National Institute of Allergy and Infectious Diseases for Lyme disease research, with payments made at least twice yearly. The stamp would be available for at least six years, beginning no later than 12 months after the bill's enactment.
AI-generated plain-language summary of the bill text — neutral, and may be imperfect. See the full text below for the exact wording.
Sponsor (1)
12 cosponsors
- Del. Norton, Eleanor Holmes [D-DC-At Large] (D-DC)
- Rep. Bacon, Don [R-NE-2] (R-NE)
- Rep. Bresnahan, Robert P. [R-PA-8] (R-PA)
- Rep. Carson, André [D-IN-7] (D-IN)
- Rep. Fitzpatrick, Brian K. [R-PA-1] (R-PA)
- Rep. Keating, William R. [D-MA-9] (D-MA)
- Rep. Lawler, Michael [R-NY-17] (R-NY)
- Rep. Lee, Summer L. [D-PA-12] (D-PA)
- Rep. Magaziner, Seth [D-RI-2] (D-RI)
- Rep. Mannion, John W. [D-NY-22] (D-NY)
- Rep. Ryan, Patrick [D-NY-18] (D-NY)
- Rep. Subramanyam, Suhas [D-VA-10] (D-VA)
Money behind the sponsor
Top reported contributors to Josh Gottheimer’s campaign committee (2024 cycle) — who funds the bill’s sponsor, not a claim about this bill. Data from FEC.
- BLACKSTONE $116,700
- APOLLO GLOBAL MANAGEMENT $71,500
- KKR & CO INC. $50,600
- CENTERVIEW PARTNERS $25,000
- FORTRESS INVESTMENT GROUP $23,200
Organizations whose employees gave the most — itemized individual contributions grouped by the donor’s reported employer (FEC Schedule A). Full finance for Josh Gottheimer → · Outside spending →
Actions (2)
- Aug 15, 2025 Referred to the Committee on Oversight and Government Reform, and in addition to the Committee on Energy and Commerce, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned. · house
- Aug 15, 2025 Introduced in House
Similar bills (6)
Bills with similar text or summary — includes reintroductions across Congresses. Ranked by semantic similarity of the bill text (computed locally); a neutral discovery aid, not a claim the bills are duplicates.
Text versions (1)
Bills are re-published as they move (Introduced → Reported → Engrossed → Enrolled …). Each stage below is a separate text; pick two to see what changed. Data from Congress.gov.
Full text
IN THE HOUSE OF REPRESENTATIVES
August 15, 2025
Mr. Gottheimer (for himself and Mr. Bacon) introduced the following bill; which was referred to the Committee on Oversight and Government Reform, and in addition to the Committee on Energy and Commerce, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned
A BILL
To provide for the issuance of a Lyme Disease Research Semipostal Stamp.
Be it enacted by the Senate and House of Representatives of the United States of America in Congress assembled,
SECTION 1. SHORT TITLE.
This Act may be cited as the “Stamp Out Lyme Disease Act”.
SEC. 2. FINDINGS AND PURPOSE.
(a) Findings.—Congress finds the following:
(1) The Centers for Disease Control and Prevention (CDC) estimate that 476,000 Lyme disease cases are diagnosed and treated in the United States annually.
(2) The CDC reports that Lyme disease is difficult to diagnose due to its diverse manifestations and a lack of reliable testing options.
(3) The National Institutes of Health (NIH) reports that a significant number of later-stage or post-treatment Lyme disease patients are not cured.
(4) The Tick-Borne Disease Working Group reports that 10 to 20 percent of Lyme disease patients will suffer from persistent symptoms which can be chronic and disabling.
(5) According to the Johns Hopkins Bloomberg School of Public Health, Lyme disease costs the United States healthcare system up to $1,300,000,000 per year.
(b) Purpose.—To afford a convenient way for members of the public to contribute to funding for Lyme disease and related tick-borne illness research within the National Institute of Allergy and Infectious Diseases, the United States Postal Service shall issue a semipostal stamp (hereinafter in this Act referred to as the “Lyme Disease Research Semipostal Stamp”) in accordance with this section.
SEC. 3. LYME DISEASE RESEARCH SEMIPOSTAL STAMP.
(a) Terms and Conditions.—The issuance and sale of the Lyme Disease Research Semipostal Stamp shall be governed by the provisions of section 416 of title 39, United States Code, and regulations issued under such section.
(b) Disposition of Proceeds.—
(1) In general.—All amounts becoming available from the sale of the Lyme Disease Research Semipostal Stamp (as determined under section 416(d) of such title 39) shall be transferred to the National Institute of Allergy and Infectious Diseases, for the purpose described in subsection (a), through payments which shall be made at least twice a year.
(2) Proceeds not to be offset.—In accordance with section 416(d)(4) of such title 39, amounts becoming available from the sale of the Lyme Disease Research Semipostal Stamp (as so determined) shall not be taken into account in any decision relating to the level of appropriations or other Federal funding to be furnished in any year to the National Institute of Allergy and Infectious Diseases.
(c) Duration.—The Lyme Disease Research Semipostal Stamp shall be made available to the public for a period of at least 6 years, beginning no later than 12 months after the date of the enactment of this Act.
(d) Definition.—For purposes of this Act, the term “semipostal stamp” refers to a stamp described in section 416(a)(1) of title 39, United States Code. <all>
Comments